FDA Officially Recommends Removal Of Interchangeability Designation From Biosimilar Labels

Agency Previously Floated The Idea In Draft Guidance In September

 
• By Chloe Kent

The US Food and Drug Administration has recommended that biosimilar drugs all use the same biosimilarity statement on their product information. Interchangeable products currently employ a separate interchangeability statement.

Pharmacist serving a patient at the counter
Interchangability relates to pharmacy-level substitution, meaning the information may be more suitable in the Purple Book rather than on labeling • Source: Shutterstock

More from Biosimilars

More from Products